Coronavirus (COVID-19) – Guidance for patients receiving services from CereHealth Corp.

Our hearts and thoughts go out to all the individuals and families across the globe who have been affected, both directly and indirectly, by COVID-19. We appreciate the healthcare workers, local communities, and the governments around the world who are on the front line working to contain this coronavirus.

With You in Mind

We recognize that COVID-19 has required all of us to be more mindful as we go through our regular daily activities. At CereScan, our core value-system centers around us being patient-centric in every endeavor. Thus, with the best interest of the patient in mind, we want to address the needs of all those who are in need of medical procedures during this unprecedented time. We are closely monitoring recommendations from the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) as we strive to help protect our patients and team members. We are committed to taking appropriate actions and providing reliable information to our patients and our healthcare providers as it comes available.

No Preventative Measure Left Undone

Ahead of any of your visits to our CereScan clinic, you can have confidence that we are taking every recommended measure to continue providing you with unparalleled care during this challenging time. From handwashing hygiene to the cleaning product specifications for our injection rooms and camera room, every safety measure is being taken with you in mind. In short, while thanking all of you who continually put your trust in our dedicated clinical staff, we want to unequivocally communicate to you that every precaution and health measure is being taken by CereScan to ensure that your imaging appointments are not disrupted by the COVID-19 virus.

What We Know

With the latest announcements from the President of the United States and the ongoing updates from the CDC and WHO concerning the spread of COVID-19, everywhere we look, someone is talking about COVID-19. However, despite all of the constant COVID-19 dialogue, there has been very limited input into how this will impact those like you who are receiving imaging evaluations. As such, CereScan is committed to providing patients with up-to-date guidance from the best available resources across the globe. As new information becomes available, CereScan will continue to provide clarity, policy, and routine updates to ensure every patient feels confident and safe as they enter our facilities for treatment.

At CereScan, in agreement with the CDC (see CDC guidelines HERE), we recommend that our patients follow the below practical guidelines to reduce the risk of spreading or contracting COVID-19:

· Wash your hands often with soap and water for at least 20 seconds.

· If water and soap are not available, you can use hand sanitizer with at least 60% alcohol.

· Avoid close contact with people who are sick.

· Avoid touching your eyes, nose, and mouth.

· Clean and disinfect frequently touched objects and surfaces within their place of residence.

Beyond simply monitoring the situation, CereScan is taking active measures to prevent the spread of COVID-19. These additional measures include:

· Limiting family or friends who might visit during an appointment.

· Added protective equipment for staff and clinicians.

· Cleaning and disinfecting patient injection room and camera room after each use.

· Cleaning and disinfecting all areas of the clinic on a nightly basis.

These above measures, along with other CereScan policy updates commensurate with the evolving global knowledge of COVID-19, will continue to provide a safe, comfortable, and welcoming place for patients to receive their evaluations.

Symptoms of COVID-19

Most people with the virus will only develop mild symptoms. Those with underlying medical conditions and the elderly are at greater risk for more severe symptoms. Symptoms can appear anywhere from 2-14 days after exposure and can include:

· Respiratory symptoms

· Fever

· Cough

· Shortness of breath

· Breathing difficulties

A CereScan team member will contact you 2 days prior to your appointment to complete a brief questionnaire. If you are experiencing any mild flu-like symptoms, it could be in the best interest of everyone involved to reschedule your appointment. If you are experiencing any of the above symptoms in a severe manner, please call your state or local health departments for testing (ensuring to call ahead of any trip to the emergency room to let them know you are coming).

Understanding and Background of COVID-19

Coronaviruses are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). COVID-19 is a new strain that was discovered in late 2019 in Asia and has spread to more than 100 countries at the time of this writing – the United States being one of the more recent countries to contract it. As with the common cold or seasonal flu, COVID-19 is transmitted through touch. This includes touching exposed surfaces or objects with the virus and then touching one’s eyes, or mouth, or the inhalation of airborne water droplets from a carrier of COVID-19.


At the CereScan clinic our patients are our number one priority. Period! We will continue to remain vigilant to prevent the spread of COVID-19 while ensuring that we do not disrupt your continuity of care. Because of our patient-centric culture, from our building to patient evaluation, we strongly believe that CereScan is the absolute safe place for receiving medical care. Come see us with supreme confidence. Rest assured, your continued confidence in CereScan is well placed.

John Kelley

Chief Executive Officer and Chairman, CereHealth Corp.

John Kelley CEO of CereScan

CereScan’s Kelley To Share His Unique Insights Into Unlocking The Mysteries Of The Human Brain As Panelist At Singularity University’s Global Forum

John Kelley, Chairman and CEO of CereScan®, will inject his inimitable style and passion for the plight of sufferers of chronic brain disorders when he addresses Singularity University’s Global Forum as a member of the Breakthrough Braintech Panel on August 15, 2017 in San Francisco. Kelley will join other innovators in discussing the connection between our biology and our inner selves and finding ways to exponentially improve our mental health.

The Global Forum is Singularity University’s flagship event and boasts a world-class collection of thinkers, leaders and doers who have come together to educate, influence and inspire others on the front lines of technical innovation.

“The chance to meet and collaborate with so many individuals who are trailblazers and barrier busters in the fields of technology and mental health is certainly my honor and privilege,” said Kelley. “The Global Forum provides a unique opportunity for us front line warriors to exchange ideas on emerging technologies and help change the direction and pace of global health.”

Featured prominently in Kelley’s presentation is CereScan’s recently unveiled CereMetrix® data analytics platform, which provides decision support and cohort analysis to medical professionals and researchers involved in diagnosing and identifying abnormalities in the human brain. CereMetrix® is a multi-variable search engine and correlative tool to support research and diagnostic applications. Through its patented neuroimaging database systems and methods, the platform is designed to accelerate the accurate and effective diagnosis of complex brain-related disorders, improving treatment and outcomes for patients.

The key attributes of CereMetrix include:

  • Unique, medical database for diagnosing complex brain-related disorders based on HD functional imagery and voxel level analysis
  • Provide a highly accurate, statistically valid standardized normative dataset for comparison and correlation of related symptomology
  • Proprietary software, scalable platform, with advanced intelligence and predicative analytics capabilities
  • Robust capabilities and easy to use
  • Accelerate accurate and effective diagnosis across the range of complex brain disorders
  • Enable appropriate diagnosis and treatment

About CereScan®

CereScan® combines state-of-the-art brain imaging technologies with a patient-centered model of care to provide the highest level of neuro-diagnostics available. CereScan utilizes state-of-the-art gamma camera technology, new generation imaging software and a proprietary process to produce comprehensive medical reports including voxel level images of brain function and physiology. Our functional brain imaging technologies are the most sophisticated in the world today. Additional information about the company is available at

CereScan® and CereMetrix® are registered trademark of CereHealth Corp.


RAM Communications
Ron Margulis, 908-272-3930

Medical innovation and progress don’t have to stop under tight federal budgets


Budget Planning

There has been a lot of discussion about Pres. Trump’s first budget submission, particularly in healthcare channels, leading to more questions than answers. Will Medicaid really be cut by billions of dollars? Are certain research programs and pharmaceutical regulations destined for the scrap heap? Will the CDC and NIH have their budgets slashed? The list goes on.

There is an excellent article in The Atlantic that provides insight into the impact of the budget on healthcare, much of which is negative for many of us in the sector. Instead of reviewing the downside, I want to focus on the opportunities and trend away from simply piling on regarding the issue the proposed budget cuts will create. These opportunities arise from having to make difficult choices based on fewer resources available to address specific challenges. It may sound counter-intuitive, but those choices over diminished fund allocations can actually lead to dramatic advancement of research in health and diagnostics.


The traditional path to innovation in healthcare is for researchers to receive money from the government and other sources, develop a solution to a specific medical challenge, seek approval from governmental bodies and then endeavor to commercialize the pharmaceutical device or process. The creative way to bring innovations to market is to secure private sector funding, then compliant testing and ultimately commercialization. This new approach is obtainable because technology has advanced to the point where data can be shared across boundaries.  This sharing accelerates innovations that are works of collaboration between many different companies and organizations. This is exactly what investors want in a business model, and has been successfully used in many industries.

The healthcare sector has operated with a margin of error that can now be reduced by deploying the latest in information systems technologies.  These new advancements enhance an organization’s ability to move new products and procedures through to commercialization more effectively. Data analytics is a great example of technology that has consistently been advancing to the point where stakeholders can fully coordinate intelligent information to better understand the needs of each patient. These stakeholders can realistically implement artificial intelligence, machine learning and other analytic technologies to fill the void and continue to be proactive in helping drive that more comprehensive view of the patient.

This research to personalize the care process is more important than ever because any potential cuts at the federal level will require more efficient use of treatment resources. If doctors can combine data sources at the point of care delivery to more precisely and immediately diagnose and treat illnesses, they can potentially save billions of dollars a year for the healthcare system.

As Harvard Business School’s Clayton Christiansen has said, machine learning is going to happen in a big way in the healthcare provider channel whether the channel likes it or not. The change will happen either through disruptive innovation, a process by which a product or service takes root initially in simple applications at the bottom of a market and then relentlessly moves up market, or through a more gradual evolution that is spurred on by existing stakeholders responding to the changing marketplace. Given those potential budget cuts, stakeholders should plan for disruptions but innovation that will be positive for the healthcare industry.

John A. Kelley, Jr., is Chairman and CEO of CereScan, a functional brain diagnostics company headquartered in Denver.

CereScan’s Latest Patent for its Neuroimaging Database Now Covers All Brain Activity Measurement Methods

CereMetrix CereScan Patent

In response to an application filed with the United States Patent and Trademark Office, CereScan® has broadened the parameters on its automated diagnostic assistance and intelligent support system, CereMetrix®, which uses quantitative measurements to assist in the diagnosis and study of complex brain disorders.  Through award of a second patent, the company may now claim exclusive use of its neuroimaging database systems and methods in the measurement of all types of brain activity.  The patent expands CereScan’s intellectual property and use of its wholly owned data warehouse, known to be the most comprehensive store of functional brain imaging data, associated patient demographic, clinical information and biomarkers worldwide.

“CereScan® is transforming the future of advanced brain diagnostics and use of intelligent learning to benefit those suffering from and studying complex brain disorders,” said John Kelley, CEO and Chairman of CereScan®. “The expansion of our patent allows us to apply key learnings to all manners of brain measurement, and vastly expands the potential for advancements in brain science using technology.”

Read More: CereScan Taps The Ohio State University to Advance Functional Brain Diagnostic System

Headquartered in Denver, CereScan® uses its patented methods, combining patient-clinical information, functional brain imaging and advanced processing software to help medical professionals identify abnormal brain physiology and activity using correlative data and pattern matching contained within its extensive data warehouse.  Through the application of technology to traditional medical practice, CereScan® has assumed a leadership role in advancing precision brain diagnostics and science.  Its first patent was awarded in September of 2014, and allowed for exclusive utilization of it systems and methods under more limited claims.

CereScan® is uniquely positioned to capitalize on a planned release of CereMetrix®, its MAaS (Medical Analytics as a Service) platform in 2017.  Its patented technology is considered by industry insiders to be a positive disruptor in the field of diagnostic radiology.  CereScan’s MAaS product suite incorporated into its CereMetrix® offering is being labeled as revolutionary, based on early feedback from Radiologists, Neurologists, and Psychiatrists who have had a chance to experiment with early release versions.

About CereScan® 
CereScan® combines state-of-the-art brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides unbiased evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit Connect with CereScan on Twitter @CereScan and on Facebook at

About CereMetrix®

CereMetrix® is an advanced healthcare analytics ecosystem that provides radiologists, practitioners and researchers with precise data about their patient’s brain health. Each new patient’s data will be compared to a library of patients with similar brain patterns, medical histories, and clinical symptoms. The unique brain diagnostic system and ever-expanding data warehouse includes over 7,000 scan encounters, including patients’ medical histories, family histories, symptoms, prior treatments, incoming diagnoses, outgoing diagnoses, and brain scans, among other data points. Each scan is composed of over 262,000 data points that measure activity levels in up to 160 brain regions derived from comparisons to normative data.